In:
International Journal of Hematologic Oncology, Future Medicine Ltd, Vol. 2, No. 4 ( 2013-08), p. 305-314
Kurzfassung:
〉 SUMMARY Decitabine is a deoxynucleoside analogue of cytidine. Its use for the treatment of acute myeloid leukemia (AML) has been recently refined. It selectively inhibits DNA methyltransferases when administered at a dose of 20 mg/m 2 by a 1-h intravenous infusion for 5 consecutive days of a 4-week cycle in the AML study. This schedule has recently been approved by the EMA as a well-tolerated alternative treatment to cytarabine or supportive care in patients aged ≥65 years with de novo or secondary AML who are not candidates for intensive chemotherapy.
Materialart:
Online-Ressource
ISSN:
2045-1393
,
2045-1407
Sprache:
Englisch
Verlag:
Future Medicine Ltd
Publikationsdatum:
2013
ZDB Id:
2692801-2
